Welcome to our dedicated page for Co-Diagnostics SEC filings (Ticker: CODX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Co-Diagnostics, Inc. (NASDAQ: CODX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Co-Diagnostics is a Utah-based molecular diagnostics company whose technologies are used in tests designed to detect and analyze nucleic acid molecules (DNA or RNA), and it files periodic and current reports that describe its financial condition, operations, capital structure and material events.
Through Forms 10-K and 10-Q, investors can review audited and interim financial statements, notes, and management’s discussion of results, including information on revenue, operating expenses, operating loss, net loss, cash and cash equivalents, and non-GAAP measures such as adjusted EBITDA. The company explains in its financial releases how adjusted EBITDA is calculated and why management uses it as a supplemental performance metric alongside GAAP results.
Current reports on Form 8-K document material events such as registered direct offerings of common stock and pre-funded warrants, securities purchase agreements, placement agency agreements, and notifications from the Nasdaq Stock Market regarding listing compliance and grace periods for the $1.00 minimum bid price requirement. Filings also cover matters like the grant of additional time to regain compliance, the intention to cure bid price deficiencies, and the implementation of a reverse stock split approved by shareholders and effected through a certificate of amendment.
Definitive proxy statements on Schedule 14A provide details about shareholder meetings and proposals, including the reverse stock split authorization, voting procedures, and record dates. Together, these filings allow users to track CODX’s capital raising activities, equity structure, governance actions and key risk disclosures directly from primary regulatory documents.
On Stock Titan, CODX filings are updated as they are posted to EDGAR and are accompanied by AI-powered summaries that highlight the main points of lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. Users can quickly see what changed, identify new financing agreements or listing updates, and locate information on topics like reverse stock splits or non-GAAP metrics without reading every page, while still having full-text filings available for deeper review.
Co-Diagnostics filed a prospectus supplement to suspend its equity distribution program to sell common stock having an aggregate offering price of up to
Co-Diagnostics insider Richard David Abbott received 220,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. After the grant Abbott beneficially owns 350,438 shares of common stock, with the 220,000 RSUs vesting in six installments beginning 11/23/2025 and continuing every six months thereafter. The Form 4 was signed 08/15/2025 and lists Abbott as President and a director.
Co‑Diagnostics, Inc. reported an insider award to Brian L. Brown, the company's Chief Financial Officer. On 08/13/2025 Mr. Brown was granted 225,000 restricted stock units (RSUs) under the issuer's 2015 Long Term Incentive Plan, as amended; each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs vest in six installments beginning 11/23/2025 and then every six months thereafter. Following the grant, the filing shows Mr. Brown beneficially owns 471,667 shares of common stock in total. The RSUs carry a reported price of $0.00, consistent with restricted units rather than an option.
Co-Diagnostics, Inc. (CODX) insider report: Dwight H. Egan, listed as Director and Chief Executive Officer, was granted 275,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan, as amended. Each RSU represents the contingent right to receive one share of common stock upon vesting. Following the grant, Mr. Egan beneficially owns 575,833 shares of common stock. The RSUs vest in six equal installments beginning 11/23/2025 and continue every six months thereafter.
Co-Diagnostics insider grant and holdings summary: Director Eugene Durenard was granted 125,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU represents the contingent right to one share of common stock upon vesting. The RSUs carry a $0.00 price and vest in six installments beginning 11/23/2025 and every six months thereafter. Following the reported transaction the filing shows 228,333 shares beneficially owned, with 103,333 common shares indicated as underlying currently reportable holdings. The Form 4 was filed by one reporting person and signed 08/15/2025.
James B. Nelson, a director of Co-Diagnostics, Inc. (CODX), was granted 125,000 restricted stock units (RSUs) on 08/13/2025. Each RSU converts to one share of common stock upon vesting, and the award shows 103,333 underlying shares currently attributable, producing 228,333 shares beneficially owned after the grant. The RSUs carry a $0.00 price and vest in six equal installments beginning 11/23/2025 and continuing every six months thereafter. The grant was reported on a Form 4 filed by the reporting person as an individual.
Co-Diagnostics, Inc. (CODX) director Richard S. Serbin was granted 125,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU converts to one share of common stock on vesting; the filing shows 103,333 shares of common stock already beneficially owned and a combined total of 228,333 shares after the grant. The RSUs have a $0.00 per-share price and vest in six installments beginning 11/23/2025 and continuing every six months thereafter. The form is signed by Mr. Serbin on 08/15/2025.
Co-Diagnostics, Inc. director Edward L. Murphy received a grant of 125,000 restricted stock units (RSUs) that convert to common stock upon vesting. Each RSU represents the right to one share. After the grant, Mr. Murphy beneficially owns 228,333 common shares in total, of which 103,333 represent previously held underlying shares and 125,000 are the newly granted RSUs. The RSUs were granted under the company’s 2015 Long Term Incentive Plan and carry an exercise/issue price of $0.00 (i.e., are compensation awards). The RSUs vest in six installments beginning on 11/23/2025 and continue every six months thereafter.
Co-Diagnostics, Inc. (CODX) reported continued operating losses and heavy customer concentration alongside notable cash inflows in the first half of 2025. The company recorded a loss per share of $(0.23) and $(0.25) for the comparable three-month periods and $(0.47) and $(0.56) for the six-month comparatives, with weighted average basic shares around 33.1 million for the most recent quarter. Grant funding dropped to $0 for both the three- and six-month periods ended June 30, 2025, versus $2.5 million and $2.7 million in the prior-year periods. Accounts receivable net balances were $210,968 at June 30, 2025 and $132,570 at December 31, 2024, with two large customers representing a majority of receivables and three customers accounting for roughly 53% of product revenue in the quarter. Cash and liquidity improved: the company reported a $8.18 million net increase in cash and cash equivalents and received net proceeds of $1.02 million from an at-the-market equity program after selling 2,209,131 shares; maturities of marketable securities generated $31.51 million. Inventory totaled $1,084,627 with reserves recorded; the company recognized inventory reserve changes of $59,591 and $101,065 for the three- and six-month periods ended June 30, 2025. Lease obligations include operating lease long-term portion of $879,258 and present value of operating lease liabilities of $1,703,716. Nasdaq notified the company of a bid-price deficiency but CODX is eligible for an additional compliance period and may cure via a reverse split if needed.